Crispr Therapeutics AG leverages CASGEVY's rollout, a robust pipeline in cardiovascular, oncology, & partnerships to large ...

In the latest close session, Vertex Pharmaceuticals (VRTX) was down 1% at $455.45. This change was narrower than the S&P 500's daily loss of 1.13%. Elsewhere, the Dow lost 1.79%, while the tech-heavy ...

The stock's fall snapped a three-day winning streak.

The biotech, known as the developer of the first CRISPR drug, will consolidate sites in the state as it stops developing a diabetes cell therapy.

Given that the Australian government heavily subsidizes pharmaceuticals— spending more than $AU16.7 billion annually through ...

Vertex is laying off 125 employees in Rhode Island and consolidating offices, following the discontinuation of a Type 1 ...

Vertex Pharmaceuticals is getting bullish attention from analysts, especially Cantor Fitzgerald, which predicts earnings of ...

According to a Worker Adjustment Retraining Notification written by Vertex to the R.I. Department of Labor and Training, ...

Vertex said in its WARN letter that the jobs will start ending on Aug. 5, and will consolidate the Providence campus.

The FDA Commissioner Marty Makary stated the FDA will reach its 2025 drug approval targets despite severe workforce ...

Vertex Pharmaceuticals is laying off workers and consolidating its real estate footprint in Rhode Island after ending a ...

The layoffs will be effective on Aug. 5, according to a letter sent to the state’s Department of Labor and Training.